Skip to main content
JCR Pharmaceuticals Co.,Ltd. logo

JCR Pharmaceuticals Co.,Ltd. — Investor Relations & Filings

Ticker · 4552 ISIN · JP3701000006 LEI · 353800IMIU9CQ1DGOS14 T Manufacturing
Open in API
Filings indexed 62 across all filing types
Latest filing 2019-11-14 Interim / Quarterly Rep…
Country JP Japan
Listing T 4552

About JCR Pharmaceuticals Co.,Ltd.

https://www.jcrpharm.co.jp/en/site/en/

JCR Pharmaceuticals is a global specialty biopharmaceutical company focused on the research, development, manufacturing, and commercialization of treatments for rare and genetic diseases. The company's portfolio includes therapies for conditions such as growth disorders, Mucopolysaccharidosis II (Hunter syndrome), and Fabry disease. A primary area of innovation involves developing treatments for central nervous system (CNS) disorders by utilizing proprietary technology to deliver biotherapeutics across the blood-brain barrier. JCR also develops and sells regenerative medicine products, aiming to address complex healthcare challenges and provide new treatment options for patients with unmet medical needs.

Recent filings

Filing Released Lang Actions
四半期報告書－第45期第2四半期(2019/07/01－2019/09/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for JCR Pharmaceuticals Co., Ltd., covering the second quarter of the 45th fiscal period (April 1, 2019, to September 30, 2019). It contains detailed financial statements, management analysis, and corporate information as required by the Financial Instruments and Exchange Act of Japan. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q2 2019
2019-11-14 Japanese
四半期報告書－第45期第1四半期(2019/04/01－2019/06/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for JCR Pharmaceuticals Co., Ltd., covering the first quarter of the 45th fiscal year (April 1, 2019, to June 30, 2019). It contains detailed financial statements, including the consolidated balance sheet, income statement, and comprehensive income statement, as well as notes to the financial statements. This meets the criteria for an Interim/Quarterly Report (IR) as it provides comprehensive financial data for a period shorter than a full fiscal year. Q1 2019
2019-08-09 Japanese
有価証券報告書－第44期(平成30年4月1日－平成31年3月31日)
Annual Report Classification · 100% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of a 10-K annual report. It contains comprehensive financial data, business information, and is filed under the Financial Instruments and Exchange Act. The document structure, including the cover page and XBRL-like metadata, confirms it is the full annual report for the fiscal year ending March 31, 2019. FY 2019
2019-06-27 Japanese
四半期報告書－第44期第3四半期(2018/10/01－2018/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for JCR Pharmaceuticals Co., Ltd. for the third quarter of the fiscal year ending March 2019. It contains detailed financial statements, including the balance sheet and income statement, and management analysis. This fits the definition of an Interim/Quarterly Report (IR). 9M 2019
2019-02-14 Japanese
四半期報告書－第44期第2四半期(2018/07/01－2018/09/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed under the Financial Instruments and Exchange Act of Japan. It contains detailed financial statements, including the balance sheet, income statement, and management analysis for the second quarter of the fiscal year ending March 2019. As it is a comprehensive financial report for a period shorter than a full fiscal year, it falls under the 'Interim / Quarterly Report' category. Q2 2019
2018-11-13 Japanese
四半期報告書－第44期第1四半期(2018/04/01－2018/06/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for JCR Pharmaceuticals Co., Ltd. for the first quarter of the 44th fiscal year (April 1, 2018, to June 30, 2018). It contains detailed financial statements, including the balance sheet, income statement, and comprehensive income statement, as well as notes to the financial statements and segment information. This meets the criteria for an Interim/Quarterly Report (IR) as it provides comprehensive financial data and analysis for a period shorter than a full fiscal year. Q1 2018
2018-08-09 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.